ClinicalTrials.gg
CompletedNCT06588491Updated Jul 24, 2026

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

A Phase 2 interventional study of Standard lymphodepletion regimen in Stiff-Person Syndrome and SPS, sponsored by Kyverna Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Kyverna Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.

Enrollment
3rd of 10
27 · median 24
Started
2024
with 2 others
Phase 2
4 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
2 of 12
Kyverna Therapeutics

Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 10th registered.

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Open to participants now

4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stiff-Person Syndrome with a site in United States, or all of them as a file.
02

Study summary

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome

Read the detailed description

Stiff person syndrome (SPS) is a rare progressive immune-mediated disorder of the central nervous system (CNS) that is characterized by progressive rigidity and painful spasms of predominantly axial and proximal limb muscles. The condition gradually worsens over time and left untreated, it can lead to permanent disability and in some cases, mortality.

B cells contribute to systemic autoimmunity and development of disease in several ways, most notably via cytokine production, antigen presentation and complement activation (via autoantibody production). In SPS, B cell involvement is supported by the presence of antibodies against glutamic acid decarboxylase (GAD), which is widely expressed within the CNS, catalyzing the conversion of the excitatory neurotransmitter l-glutamate to the inhibitory GABA.

CAR-T therapy such as KYV-101 may be an effective treatment for SPS, by targeting these autoreactive B cells. Using chimeric antigen receptor (CAR) T-cell technology, engineered T cells with receptors are designed to recognize and eliminate B cells, including those that produce GAD autoantibodies. This approach aims to intervene at the root of the autoimmune response, offering a precise and potentially transformative treatment for SPS. CAR-T cell therapy holds promise as a targeted and effective intervention, addressing the autoimmune component directly and potentially halting disease progression.

03

Conditions studied

  • Stiff-Person Syndrome
  • SPS

Browse trials for

Keywords

  • SPS
  • Stiff-Person Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject must have been diagnosed SPS per the following criteria:

    • Rigidity of limb and axial (trunk) muscles prominent in the abdominal and thoracolumbar paraspinal areas and making bending difficult
    • Clinical or electrophysiological evidence of continuous contraction of agonist and antagonist muscles
    • Episodic spasms precipitated by unexpected noises, tactile stimuli, or emotional upset
    • Absence of any other neurologic disease that could explain the stiffness and rigidity
    • High titer serum anti-GAD65 antibodies shown at screening -OR- seropositive for anti-glycine antibodies. If anti-GAD65 antibodies are lower than the high titer threshold peripherally but positive in the cerebrospinal fluid (CSF), the subject can be included. A prior documented high titer anti-GAD65 antibody level may be acceptable subject to sponsor review.
  • Active symptoms with inadequate response to at least one immunomodulatory therapy.
  • Stiffness index ≥2.
  • At least 20 of the 25 enrolled subjects should be ambulatory.

Key Exclusion Criteria:

  • Bedridden subjects for more than 3 months.
  • History of CNS or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, sarcoidosis, non-SPS progressive neurologic condition or progressive multifocal leukoencephalopathy (PML).
  • History of stroke, seizure, dementia, Parkinson's disease, cerebellar diseases, psychosis, aphasia, and any other neurologic disorder that is of a nature and severity that the investigator considers would increase the risk for the subject.
  • Cardiac ≤ 40%.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning

    Dosing with KYV-101 CAR T cells

    Biological: Standard lymphodepletion regimen

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate efficacy of KYV-101

    Change in the Timed 25-Foot Walk (T25-FW) from baseline

    Time frame: Up to 12 months

  2. To evaluate the safety of KYV-101

    Incidence of adverse events and laboratory abnormalities

    Time frame: Up to 12 months

Secondary outcomes

  1. To evaluate efficacy of KYV-101

    Change in Modified Rankin Scale from baseline Modified Rankin Scale: Scoring is from 0 (no symptoms) to 6 (death). A higher score indicates a worse outcome.

    Time frame: Up to 12 months

  2. To evaluate efficacy of KYV-101

    Change in the scores of the distribution-of-stiffness index from baseline. Distribution of Stiffness Index: Scoring is from 0 to 6. A higher score indicates a worse outcome.

    Time frame: Up to 12 months

  3. To evaluate efficacy of KYV-101

    Change in Hauser Ambulation Index. Hauser Ambulation Index: Scoring is from 0 to 9. A higher score indicates a worse outcome.

    Time frame: Up to 12 months

  4. To evaluate efficacy of KYV-101

    Change in Heightened sensitivity scale. Heightened Sensitivity Scale: Scoring is from 0 to 7. A higher score indicates a worse outcome.

    Time frame: Up to 12 months

Other outcomes

  1. To evaluate efficacy of KYV-101

    6-minute walk test

    Time frame: Up to 12 months

  2. To evaluate efficacy of KYV-101

    Change in anti-GAD-65 antibody levels

    Time frame: Up to 12 months

  3. To evaluate efficacy of KYV-101

    Change in anti-glycine receptor antibodies

    Time frame: Up to 12 months

  4. To evaluate efficacy of KYV-101

    36-Short form survey (SF-36). The SF-36 has eight scaled scores. Scores range from 0 - 100 with lower scores equating to more disability and higher scores equating to less disability.

    Time frame: Up to 12 months

  5. To characterize the pharmacokinetics (PK)

    Levels of KYV-101 CAR-positive T cells in the blood

    Time frame: Up to 12 months

  6. To evaluate the immunogenicity (humoral response) of KYV-101

    Percentage of participants who develop anti-KYV-101 antibodies by immunoassays

    Time frame: Up to 12 months

  7. To characterize the pharmacodynamics (PD)

    Levels of systemic cytokine concentrations in serum

    Time frame: Up to 12 months

  8. To characterize the pharmacodynamics (PD)

    Levels of B cells in the blood

    Time frame: Up to 12 months

07

Study locations

3 sites
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Publications

  • Piquet AL, et al. Miv-cel CD19 CAR T-cell therapy shows efficacy and safety in stiff person syndrome in a pivotal, multicenter, phase 2 study (KYSA-8). Presented at: American Academy of Neurology (AAN) Annual Meeting; April 18-21, 2026; Chicago, IL. Late Breaking Science Abstract 008.
  • Dalakas MC. Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3):e200109. doi: 10.1212/NXI.0000000000200109. Print 2023 May. PubMed 37059468 ↗
  • Duddy ME, Baker MR. Stiff person syndrome. Front Neurol Neurosci. 2009;26:147-165. doi: 10.1159/000212375. Epub 2009 Apr 6. PubMed 19349711 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jun 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Sep 25, 2024
Primary completionActual
Jun 25, 2026
CompletionActual
Jun 25, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588491
Lead sponsor
Kyverna Therapeutics
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 25, 2024
Primary completion
Jun 25, 2026
Completion
Jun 25, 2026
Last update
Jul 24, 2026

Study contacts

MD
study director · Kyverna Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunosuppressive Agents

Start the discussion